Skip to main content

Table 1 Clinical and biomarkers characteristics in amyloidosis patients by cardiac involvement (CI) and survival status

From: Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters

Parameters All patients (n = 74) With CI (n = 42) Without CI (n = 32) P value Non-survivors (n = 20) Survivors (n = 54) P value
Age (years) 57.6 ± 10.0 57.8 ± 10.2 57.2 ± 9.9 0.778 57.0 ± 11.4 57.78 ± 9.5 0.769
Male (%) 38 (51.4) 25 (59.5) 13 (40.6) 0.107 12 (60) 26 (48.1) 0.365
BSA (m2) 1.68 ± 0.15 1.68 ± 0.17 1.68 ± 0.12 0.938 1.66 ± 0.17 1.68 ± 0.14 0.599
SBP (mm Hg) 116 ± 17 114 ± 18 119 ± 16 0.211 109 ± 15 119 ± 17 0.049
DBP (mm Hg) 73 ± 12 71 ± 9 75 ± 14 0.226 69 ± 10 74 ± 12 0.102
HR (beats/min) 81 ± 15 83 ± 15 78 ± 15 0.129 88 ± 13 78 ± 15 0.012
Mayo stage
 I and II (%) 43 (58.1) 11 (26.2) 32 (100) < 0.001 7 (35) 36 (66.7) 0.014
 III and IV (%) 31 (41.9) 31 (73.8) 0 (0)   13 (65) 18 (33.3)  
 Troponin I (ng/mL) 0.04 (0.15) 0.10 (0.27) 0.01 (0.02) < 0.001 0.15 (0.41) 0.025 (0.07) 0.003
 cTnT (ng/mL) 0.03 (0.06) 0.06 (0.11) 0.02 (0.02) < 0.001 0.10 (0.14) 0.03 (0.04) 0.001
 NT-proBNP (pg/ml) 769 (2901) 2436 (6514) 348 (476) < 0.001 4062 (8126) 504 (1578) < 0.001
 FLC-diff(mg/L) 45.0 (88.2) 75.7 (106.3) 27.3 (57.4) 0.111 100.8 (82.9) 23.9 (87.6) 0.094
 Serum creatinine (μmol/L) 88.0 (32) 92.5 (39.3) 84.5 (22.3) 0.194 93.5 (56.3) 86.5 (29.8) 0.139
 eGFR (ml/min/1.73m2) 69.4 ± 23.7 74.0 ± 25.9 66.0 ± 21.6 0.154 61.6 ± 21.6 72.4 ± 24.1 0.083
 24 h urinary protein (g/day) 2.27 (2.23) 2.33 (2.75) 2.27 (2.06) 0.966 1.95 (3.19) 2.34 (2.11) 0.904
  1. BSA body surface area, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, (FLC-diff) free light chain differential, eGFR estimated glomerular filtration rate